Document Detail

Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
MedLine Citation:
PMID:  15389273     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the long-term efficacy and safety of infliximab as treatment for noninfectious posterior uveitis. METHODS: An open-label clinical trial including seven patients (12 eyes) with posterior uveitis refractory to conventional treatment regimens with corticosteroids and at least one immunosuppressive agent. Three intravenous doses of 5 mg/kg of infliximab were administered at weeks 0, 2, and 6. Infliximab infusion was repeated in patients undergoing a relapse of uveitis after initial remission. Improvement was defined as amelioration of visual acuity or disappearance of retinal exudates and/or haemorrhages, decreased macular oedema and/or vitreous opacities. All patients were followed up for at least 36 months. RESULTS: Six of the seven patients (five diagnosed with Behçet's disease and one diagnosed with sarcoidosis) showed a significant improvement after the first infliximab dose. Only in one patient diagnosed with chronic idiopathic multifocal choroiditis did the drug have no effect, and this patient was withdrawn from the study. At the end of follow-up, one eye had lost one line of vision and three eyes showed improved vision. All eyes had improved in terms of signs of inflammation. No adverse effects of treatment were observed. CONCLUSION: Infliximab is efficient and safe for the long-term management of refractory posterior uveitis, especially in patients with predominant retinal vasculitis and vitritis.
J M Benitez-del-Castillo; J M Martinez-de-la-Casa; E Pato-Cour; R Méndez-Fernández; C López-Abad; M Matilla; J Garcia-Sanchez
Related Documents :
18404273 - Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy.
19633973 - Bevacizumab versus ranibizumab in the treatment of exudative age-related macular degene...
3445813 - Electroepilation using insulated needles.
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  Eye (London, England)     Volume:  19     ISSN:  0950-222X     ISO Abbreviation:  Eye (Lond)     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-08-08     Completed Date:  2006-01-12     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  8703986     Medline TA:  Eye (Lond)     Country:  England    
Other Details:
Languages:  eng     Pagination:  841-5     Citation Subset:  IM    
Department of Ophthalmology, Instituto de Investigaciones Oftalmológicas Ramón Castroviejo, Hospital Clínico San Carlos, Universidad Complutense de Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / therapeutic use*
Behcet Syndrome / drug therapy,  physiopathology
Drug Administration Schedule
Immunosuppressive Agents / therapeutic use*
Middle Aged
Prospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Uveitis, Posterior / drug therapy*,  physiopathology
Visual Acuity
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Immunosuppressive Agents; 0/Tumor Necrosis Factor-alpha; 0/infliximab
Comment In:
Eye (Lond). 2005 Aug;19(8):831-3   [PMID:  16086039 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Relation between the axial length and lenticular progressive myopia.
Next Document:  Primary retinal reattachment surgery: anatomical and functional outcome in phakic and pseudophakic e...